Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Real-world data on melanoma brain metastases and survival outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Arginase-2 as a target for cancer immune therapy

    Publikation: Bog/antologi/afhandling/rapportPh.d.-afhandlingForskning

  4. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

One way that tumors evade immune destruction is through tumor and stromal cell expression of arginine-degrading enzyme arginase-2 (ARG2). Here we describe the existence of pro-inflammatory effector T-cells that recognize ARG2 and can directly target tumor and tumor-infiltrating cells. Using a library of 34 peptides covering the entire ARG2 sequence, we examined reactivity toward these peptides in peripheral blood mononuclear cells from cancer patients and healthy individuals. Interferon-γ ELISPOT revealed frequent immune responses against several of the peptides, indicating that ARG2-specific self-reactive T-cells are natural components of the human T-cell repertoire. Based on this, the most immunogenic ARG2 protein region was further characterized. By identifying conditions in the microenvironment that induce ARG2 expression in myeloid cells, we showed that ARG2-specific CD4T-cells isolated and expanded from a peripheral pool from a prostate cancer patient could recognize target cells in an ARG2-dependent manner. In the 'cold' in vivo tumor model Lewis lung carcinoma, we found that activation of ARG2-specific T-cells by vaccination significantly inhibited tumor growth. Immune-modulatory vaccines targeting ARG2 thus are a candidate strategy for cancer immunotherapy.

OriginalsprogEngelsk
TidsskriftOncoImmunology
Vol/bind9
Udgave nummer1
Sider (fra-til)1771142
ISSN2162-4011
DOI
StatusUdgivet - 1 jun. 2020

Bibliografisk note

© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

ID: 61243545